Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Wednesday, January 11, 2012

Pharmacogenetic testing and research

Athough MEBO Research does not intend to start pharmacogenetic testing at the present time, it is noteworthy how significant a person’s ability to metabolize medication is in order to obtain the desired therapeutic effect intended by the physician. Pharmaceutical companies have been concerned with this concept, as noted in the AmpliChip CYP450 Test from the pharmaceutical company, Roche. This test is the world’s first microarray-based parmacogenomic test cleared for clinical use. According to Roche,

The AmpliChip CYP450 Test provides comprehensive detection of gene variations — including deletions and duplications — for the CYP2D6 and CYP2C19 genes, which play a major role in the metabolism of an estimated 25% of all prescription drugs. It is intended to be an aid to clinicians in determining therapeutic strategy and treatment dose for therapeutics metabolized by the CYP2D6 or CYP2C19 gene product.

It would be interesting to look into the possibility of carrying out genetic research sometime in the future to find specific gene types that determine how medicines are metabolized in sufferers of body odor and halitosis conditions in comparison to a non-sufferer control group. Perhaps this would be of mutual interest to both, pharmaceutical companies and sufferers, especially those whose physician wants to prescribe psychiatric medication or are taking other medications for other medical conditions. Perhaps MEBO might be able to tap into pharmaceutical company funding for such a study within the next couple of years.

This explosion of biologic information about the proteins and pathways relevant to cellular physiology and disease has stimulated biotechnology and pharmaceutical researchers to assign top priority to identification and validation of key targets (known or novel) to develop therapies for the many remaining diseases. Hypothesis-based biological research is now supplemented with multidisciplinary approaches to systems and circuit-based biology that integrate bioinformatics, genomic databases, and cellular and molecular biology with the traditional drug discovery disciplines of physiological biochemistry, pharmacology, and medicinal chemistry. As a consequence, interventional strategies now include recombinant proteins, monoclonal antibodies, peptides, and small organic molecules as drug candidates. The goal is to expedite the testing of novel therapeutic hypotheses in humans and to develop strategies to identify optimal therapy for individual patients.

Additional information:

halitosis research
María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
The MEBO Forum Please sign the MEBO Petition

body odor petition
MEBO Research


Post a Comment